Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy.
Joyce K HwangArchana M AgarwalJames BrugarolasTian ZhangPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Subset analysis of patients with sarcomatoid renal cell carcinoma (sRCC) included in the CheckMate 214 trial of ipilimumab-nivolumab versus sunitinib showed improved outcomes in sRCC with ipilimumab-nivolumab. The use of checkpoint inhibitor-based regimens in sRCC, for which therapeutic options were once limited, is further supported by additional clinical trials.See related article by Tannir et al., p. 78.